Breaking News Instant updates and real-time market news.

BDX

Becton Dickinson

$170.31

-0.38 (-0.22%)

, ILMN

Illumina

$136.18

0.99 (0.73%)

07:08
11/29/16
11/29
07:08
11/29/16
07:08

Piper sees tax holiday as potential catalyst for Medical Diagnostics space

A repatriation tax holiday represents a potential catalyst for the Medical Diagnostics space, Piper Jaffray analyst William Quirk tells investors in a research note. Quirk notes that Becton Dickinson (BDX), Illumina (ILMN) and PerkinElmer (PKI) disclose cash held overseas and that all have highlighted share repurchases and acquisitions as priorities. He believes a repatriation event could be a catalyst for small lab deals. Acquisition targets include CareDx (CDNA), Genomic Health (GHDX), Oxford Immunotec (OXFD), Trovagene (TROV) and Veracyte (VCYT), Quirk tells investors.

BDX

Becton Dickinson

$170.31

-0.38 (-0.22%)

ILMN

Illumina

$136.18

0.99 (0.73%)

PKI

PerkinElmer

$50.94

-0.6 (-1.16%)

CDNA

CareDx

$3.75

-0.1 (-2.60%)

GHDX

Genomic Health

$30.91

-0.59 (-1.87%)

OXFD

Oxford Immunotec

$14.70

0.14 (0.96%)

TROV

Trovagene

$2.95

-0.15 (-4.84%)

VCYT

Veracyte

$7.68

-0.07 (-0.90%)

  • 29

    Nov

  • 30

    Nov

  • 04

    Dec

  • 07

    Dec

BDX Becton Dickinson
$170.31

-0.38 (-0.22%)

11/18/16
LEER
11/18/16
NO CHANGE
Target $185
LEER
Market Perform
Becton Dickinson price target raised to $185 from $180 at Leerink
Leerink analyst Richard Newitter raised his price target for Becton Dickinson to $185 from $180 following the company's analyst event. Nonetheless, the analyst reiterates a Market Perform rating on the shares as he continues to believe there are better return/growth profiles elsewhere in his large cap coverage and thinks the valuation premium implied by his price target adequately gives credit for upside potential.
09/23/16
09/23/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from Sector Perform by RBC analyst Mark Mahaney, who cut his price target to $14 from $17. The research firm's survey of more than 1,100 advertising professionals and their attitudes towards Facebook (FB), Google (GOOG), Twitter and other high-profile names showed that, despite marketing budgets continuing to shift online, interest in the microblog platform appears to be declining. Of note, Twitter shares have surged this morning after CNBC's David Faber reported that Twitter is moving closer to selling itself and has received expressions of interest in a possible sale, although no deal is imminent. 2. Yum! Brands (YUM) downgraded to Outperform from Top Pick by RBC Capital analyst David Palmer based on valuation. His price target on Yum shares remains $97. 3. Becton Dickinson (BDX) downgraded to Sell from Neutral by Citi analyst Amit Hazan, who thinks a cyclical U.S. slowdown will push the company's organic growth below expectations. The analyst, who also sees a diminishing impact on Becton's growth from emerging markets, cut his price target for the shares to $165 from $167. 4. NextEra Energy (NEE) downgraded to Hold from Buy by Deutsche Bank analyst Jonathan Arnold, as he sees limited near-term upside with the shares up 23% year-to-date. "Extraordinarily frosty commentary" from two of three PUCT commissioners yesterday regarding NextEra's Oncor deal indicates an uphill battle in getting it approved, Arnold tells investors. 5. AVANGRID (AGR) downgraded to Underweight from Neutral by JPMorgan analyst Christopher Turnure, who thinks both the company's growth guidance and consensus expectations "appear ambitious." He lowered his price target for the shares to $41 and $44 and notes he does not have confidence in AVANGRID's near-term growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
SBSH
09/23/16
DOWNGRADE
Target $165
SBSH
Sell
Becton Dickinson downgraded to Sell from Neutral at Citi
Citi analyst Amit Hazan downgraded Becton Dickinson to Sell saying a cyclical U.S. slowdown will drive the company's organic growth below expectations. The analyst also sees a diminishing impact on Becton's growth from emerging markets. He cut his price target for the shares to $165 from $167.
05/26/16
PIPR
05/26/16
NO CHANGE
PIPR
Piper sees limited impact from new European device tax rules
Piper Jaffray analyst William Quirk points out that the European Union announced it will issue new rules for medical devices and in vitro diagnostics in the near-to-mid term. The EU is looking to strengthen rules for clearing devices/tests for the market and increase existing device/test surveillance, Quirk tells investors in a research note. He believes the new rules should not inhibit well validated tests/devices from coming to market. As such, Quirk expects little impact to Piper's in vitro diagnostic coverage universe, namely Accelerate Diagnostics (AXDX), Becton Dickinson (BDX), Cepheid (CPHD), Hologic (HOLX), Quidel (QDEL) and Meridian Bioscience (VIVO).
ILMN Illumina
$136.18

0.99 (0.73%)

11/02/16
FANA
11/02/16
DOWNGRADE
Target $116
FANA
Underweight
Illumina downgraded to Underweight from Equal-Weight at First Analysis
First Analysis analyst Joseph Munda downgraded Illumina to Underweight saying the valuation is too high given management's "unconvincing arguments about the outlook," his concerns regarding overcapacity and a "continued lack of new products in the near-term pipeline." The analyst lowered his price target for the shares to $116 from $130 following Illumina's Q3 results.
10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/16
JANY
10/11/16
DOWNGRADE
JANY
Sell
Illumina downgraded to Sell from Neutral at Janney Capital
11/10/16
LEER
11/10/16
INITIATION
Target $145
LEER
Market Perform
Illumina resumed with a Market Perform at Leerink
Leerink analyst Puneet Souda resumed coverage of Illumina with a Market Perform rating and $145 price target.
PKI PerkinElmer
$50.94

-0.6 (-1.16%)

08/05/16
MZHO
08/05/16
DOWNGRADE
Target $56
MZHO
Neutral
PerkinElmer downgraded to Neutral from Buy at Mizuho
Mizuho analyst Eric Criscuolo downgraded PerkinElmer to Neutral citing valuation following the company's Q2 results with the stock near his $56 price target. The analyst sees "no strong driver: to push the valuation higher.
07/26/16
CANT
07/26/16
NO CHANGE
Target $173
CANT
Buy
Waters price target raised to $173 from $163 at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier raised his price target for Waters Corporation (WAT) to $173 and recommends buying the stock following the company's "strong" Q2 results and raised guidance. The analyst keeps a Buy rating on the name. Regarding a read-through to Bruker (BRKR), Brokmeier notes that Waters' academic market was broadly weak during the quarter. He remains positive on the shares, but is hesitant to call Waters' quarter an incremental positive for Bruker. The analyst prefers shares of PerkinElmer (PKI), which he notes has a higher exposure to the biopharma end market.
06/24/16
CANT
06/24/16
NO CHANGE
CANT
'Brexit' slight negative for life science tools, diagnostics space, says Cantor
Cantor analyst Bryan Brokmeier believes that while industry fundamentals remain intact and the sector does not have a high exposure to the macro environment, tools companies do have high currency exposure and may face multiple contraction following the "Brexit" vote. With less exposure to market turmoil than molecular diagnostic companies, which trade at high multiples, Brokmeier prefers life science tools companies, adding that he is bullish on PerkinElmer (PKI) and Waters (WAT), which he sees as "more stable" businesses.
09/22/16
UBSW
09/22/16
NO CHANGE
Target $61
UBSW
Buy
PerkinElmer still an underappreciated story, says UBS
UBS analyst Jonathan Groberg believes PerkinElmer remains an underappreciated story. The analyst said his buy thesis remains unchanged as management has executed well on its plan to streamline and invest in core businesses. Groberg reiterated its Buy rating and raised his price target to $61 from $56 on PerkinElmer shares, also citing expectations the company will be able to expand margins and the stock's compelling relative valuation.
CDNA CareDx
$3.75

-0.1 (-2.60%)

06/13/16
LEER
06/13/16
NO CHANGE
LEER
CMS price proposals for diagnostic tests a negative for most, says Leerink
Leerink analyst Dan Leonard expects several diagnostics stocks to underperform following proposed price cuts or low initial reimbursement rates by the Centers for Medicare and Medicaid Services, or CMS, for diagnostic tests. If finalized, the preliminary pricing would negatively impact CareDx (CDNA), Veracyte (VCYT), and InVitae (NVTA), the analyst tells investors in a research note, adding that he also sees an indirect negative read-through for Illumina (ILMN).
06/20/16
PIPR
06/20/16
NO CHANGE
PIPR
Final PAMA rule better than expected, says Piper Jaffray
Piper Jaffray analyst William Quirk says the final Protecting Access to Medicare Act published Friday by Centers for Medicare & Medicaid Services is better than expected. PAMA is delayed until 2018 from 2017 as expected, Quirk tells investors in a research note. Hospital labs will be required to submit private payer rates to CMS, a positive relative to prior expectations, the analyst notes. He views the decision as beneficial for Quest Diagnostics (DGX) and LabCorp (LH). Further, CMS will require labs to submit only in-network rates and out-of-network "final" rates, which is a positive for specialty labs who have in-network rates at or above Medicare including CareDx (CDNA), Genomic Health (GHDX), Myriad Genetics (MYGN), Oxford Immunotec (OXFD) and Veracyte (VCYT), Quirk writes.
06/13/16
CANT
06/13/16
NO CHANGE
Target $13
CANT
Buy
Cantor sees 'flawed methodology' with new CMS rates
Cantor Fitzgerald analyst Bryan Brokmeier says shares of Veracyte (VCYT) may be under pressure this morning following Friday's release of a proposed gapfill Medicare reimbursement rate reduction on the company's Afirma GEC. Along with the 30% reduction on Afirma's GEC, the release from the Centers for Medicare and Medicaid Services resets rates on 15 other molecular diagnostic tests, including reductions in CareDx's (CNDA) AlloMap, which is down 74%, Genomic Health's (GHDX) Oncotype Dx Colon, which is down 73%, and Rosetta Genomics' (ROSG) Cancer Origin Test, which is down 57%, Brokmeier tells investors in a research note. The analyst, however, believes the preliminary proposed gapfill rate is based on a "flawed methodology" because it is the median proposed rate submitted by all Medicare Administrative Contractors, including those that have little or no experience administering claims on these tests, Brokmeier contends. He points out that Medicare represents approximately 20% of Afirma GEC test volume for Veracyte. Based on 2015 volume, the 30% Medicare rate reduction for Afirma would reduce total revenues by $3.7M or 7.5%, he adds. The analyst keeps a Buy rating on Veracyte with a $13 price target.
07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).
GHDX Genomic Health
$30.91

-0.59 (-1.87%)

06/21/16
LEER
06/21/16
NO CHANGE
Target $38
LEER
Outperform
Leerink remains confident on Genomic Health revenue acceleration story
Leerink analyst Dan Leonard remains confident that Genomic Health's revenue acceleration could lead to multiple expansion, adding that recent due diligence highlights efforts to drive growth in the core breast franchise. The analyst reiterates an Outperform rating and $38 price target on the shares.
OXFD Oxford Immunotec
$14.70

0.14 (0.96%)

06/24/16
PIPR
06/24/16
NO CHANGE
Target $25
PIPR
Overweight
Piper Jaffray positive on Imugen acquisition by Oxford Immunotec
Piper Jaffray analyst William Quirk says the acquisition of Imugen, a clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, by Oxford Immunotec is a "good strategic fit" given call point overlap. Oxford's vision is to leverage the exiting sales force and marketing infrastructure to grow its revenue in the U.S., the analyst tells investors in a research note. Quirck also notes that Oxford has more costs than revenue in GBP and today's GBP/USD movements following the "Brexit" vote could be a net benefit. He reiterates an Overweight rating and $25 price target on Oxford's shares.
TROV Trovagene
$2.95

-0.15 (-4.84%)

09/30/16
CANT
09/30/16
NO CHANGE
CANT
Trovagene outlook has improved, says Cantor
After meeting with Trovagene's management, Cantor analyst Bryan Brokmeier is more upbeat on the stock. He says that the company's new strategy :"significantly reduces" its cash needs, provides it with multiple potential positive catalysts and reduces its competition. The analyst keeps an $8 price target and Buy rating on the shares.
08/08/16
CANT
08/08/16
UPGRADE
Target $7
CANT
Buy
Trovagene upgraded to Buy with $7 target at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier upgraded Trovagene to Buy from Hold citing the company's accelerating clinical business. In Q2, the company increased the number of physicians on the platform to approximately 700 physicians from 550 in Q1, Brokmeier tells investors in a research note. He points out that Trovagene is also targeting new biopharma collaborations. The analyst raised his price target for the shares to $7 from $5.
08/08/16
CANT
08/08/16
UPGRADE
CANT
Buy
Trovagene upgraded to Buy from Hold at Cantor
VCYT Veracyte
$7.68

-0.07 (-0.90%)

11/22/16
LEER
11/22/16
NO CHANGE
Target $12
LEER
Outperform
CLFS 2017 rates a clear positive for Veracyte, says Leerink
Leerink analyst Puneet Souda notes that the Centers for Medicare and Medicaid Services, or CMS, released its Clinical Laboratory Fee Schedules, or CLFS, final determination or final pricing on a number of tests for 2017 including Veracyte's Afirma. The analyst sees the company's Afirma Thyroid FNA GEC pricing increase as a clear positive for Veracyte as it eliminates both near-term uncertainty and saves the company from an expected $1.6M impact in 2017. He reiterates an Outperform rating and $12 price target on the shares.
11/14/16
LEER
11/14/16
INITIATION
Target $12
LEER
Outperform
Veracyte reinstated with an Outperform at Leerink
Leerink analyst Puneet Souda resumed coverage of Veracyte with an Outperform rating and $12 price target, saying it is gaining traction as reimbursement continues to tilt the scale.
10/18/16
CANT
10/18/16
NO CHANGE
CANT
Veracyte should be bought at current levels, says Cantor
After Veracyte preannounced higher than expected revenue, Cantor analyst Bryan Brokmeier says that the revenue beat indicates that the company's reimbursement trends are improving. The analyst thinks that the company is well-positioned to continue getting reimbursed for its tests, and he says that the stock's valuation is "compelling." The analyst recommends buying the shares at current levels.
09/08/16
CANT
09/08/16
NO CHANGE
Target $13
CANT
Buy
Cantor says buy Veracyte following draft local coverage determination
Cantor analyst Bryan Brokmeier recommends that investors buy shares of Veracyte following the announced draft local coverage determination, or LCD, for the company's Percepta Bronchial Genomic Classifier. The analyst says this draft LCD with Noridian Healthcare Solutions represents over 30M covered lives for its Percepta and represents more than 25% of the U.S. market opportunity. Further, Brokmeier believes other Medicare Administrative Contractors will follow Noridian's lead. The analyst reiterates a Buy rating and $13 price target on the shares.

TODAY'S FREE FLY STORIES

IBM

IBM

$169.12

0.47 (0.28%)

08:23
01/19/18
01/19
08:23
01/19/18
08:23
Recommendations
IBM analyst commentary  »

IBM price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJT

DJ Transportation Average

08:22
01/19/18
01/19
08:22
01/19/18
08:22
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$203.27

0.12 (0.06%)

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$67.67

0.12 (0.18%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$76.48

-0.63 (-0.82%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$104.69

-0.09 (-0.09%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNC

Lincoln National

$83.06

0.08 (0.10%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Conference/Events
Lincoln National to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 01

    Feb

XLB

S&P Select Materials SPDR

$62.90

-0.04 (-0.06%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$50.14

-0.32 (-0.63%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$57.39

-0.17 (-0.30%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$88.11

0.02 (0.02%)

08:18
01/19/18
01/19
08:18
01/19/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWCH

Switch

$17.02

-0.25 (-1.45%)

08:18
01/19/18
01/19
08:18
01/19/18
08:18
Initiation
Switch initiated  »

Switch initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$156.54

-1.08 (-0.69%)

08:18
01/19/18
01/19
08:18
01/19/18
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$260.16

-0.92 (-0.35%)

08:18
01/19/18
01/19
08:18
01/19/18
08:18
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLPN

Dolphin Entertainment

$3.15

-0.1 (-3.08%)

08:17
01/19/18
01/19
08:17
01/19/18
08:17
Initiation
Dolphin Entertainment initiated  »

Dolphin Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.14

-0.47 (-0.17%)

08:17
01/19/18
01/19
08:17
01/19/18
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$29.33

-0.04 (-0.14%)

08:17
01/19/18
01/19
08:17
01/19/18
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$106.67

0.78 (0.74%)

08:17
01/19/18
01/19
08:17
01/19/18
08:17
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

PowerShares QQQ Trust

$165.82

0.03 (0.02%)

08:16
01/19/18
01/19
08:16
01/19/18
08:16
Technical Analysis
PowerShares QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

08:16
01/19/18
01/19
08:16
01/19/18
08:16
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDX

Nasdaq 100 Index

$6,811.38

1.09471 (0.02%)

08:16
01/19/18
01/19
08:16
01/19/18
08:16
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:15
01/19/18
01/19
08:15
01/19/18
08:15
General news
Boston Fed dove Bostic will be taking part in an "informal discussion" »

Boston Fed dove Bostic…

SYF

Synchrony

$37.30

-0.76 (-2.00%)

, PYPL

PayPal

$82.94

0.47 (0.57%)

08:14
01/19/18
01/19
08:14
01/19/18
08:14
Hot Stocks
Synchrony comments on 2018 outlook in presentation slides »

Synchrony's (SYF)…

SYF

Synchrony

$37.30

-0.76 (-2.00%)

PYPL

PayPal

$82.94

0.47 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.